open access

Vol 74, No 4 (2015)
ORIGINAL ARTICLES
Published online: 2015-11-27
Submitted: 2015-01-06
Accepted: 2015-02-23
Get Citation

The ameliorative potential of Hyphaene thebaica on streptozotocin-induced diabetic nephropathy

M. AbdEl-moniem, H. N. Mustafa, H. A. Megahed, M. H. Agaibyi, G. A. Hegazy, M. A. El-Dabaa
DOI: 10.5603/FM.2015.0106
·
Pubmed: 26620504
·
Folia Morphol 2015;74(4):447-457.

open access

Vol 74, No 4 (2015)
ORIGINAL ARTICLES
Published online: 2015-11-27
Submitted: 2015-01-06
Accepted: 2015-02-23

Abstract

Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. The aim of the current study is to investigate the possible beneficial effects of Hyphaene thebaica in DN.

Materials and methods: For this, 50 male albino rats were divided into five groups: group I — represented the control group; group II — received Hyp­haene thebaica extracts of 150 mg/kg BW by oral gavage for 6 weeks; group III — received single intraperitoneal injections of streptozotocin (50 mg/kg BW) to induce type-2 diabetes mellitus; group IV (protective) — diabetic rats recei­ved Hyphaene thebaica extract (150 mg/kg BW) orally for 6 weeks; group V (curative) — received Hyphaene thebaica extract (150 mg/kg BW) orally after the diagnosis of DN.

Results: In the DN protected group, blood glucose, urea, and creatinine decreased significantly, while insulin and C-peptide increased significantly. Moreover, cystatin C and neutrophil gelatinase-associated lipocalin decreased. Collagen fibre deposition is increased with an apparent thickening of the parietal layer of Bowman’s capsules and the basal lamina of convoluted tubules, as well as increase of the immune-reaction of caspase-3 and desmin. The introduction of Hyphaene thebaica led to greater amelioration in the biochemical markers, apoptotic alterations, and podocyte injuries of the protected group than in the curative group.

Conclusions: Hyphaene thebaica may be advised as a good choice that can delay diabetic renal complications.

Abstract

Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. The aim of the current study is to investigate the possible beneficial effects of Hyphaene thebaica in DN.

Materials and methods: For this, 50 male albino rats were divided into five groups: group I — represented the control group; group II — received Hyp­haene thebaica extracts of 150 mg/kg BW by oral gavage for 6 weeks; group III — received single intraperitoneal injections of streptozotocin (50 mg/kg BW) to induce type-2 diabetes mellitus; group IV (protective) — diabetic rats recei­ved Hyphaene thebaica extract (150 mg/kg BW) orally for 6 weeks; group V (curative) — received Hyphaene thebaica extract (150 mg/kg BW) orally after the diagnosis of DN.

Results: In the DN protected group, blood glucose, urea, and creatinine decreased significantly, while insulin and C-peptide increased significantly. Moreover, cystatin C and neutrophil gelatinase-associated lipocalin decreased. Collagen fibre deposition is increased with an apparent thickening of the parietal layer of Bowman’s capsules and the basal lamina of convoluted tubules, as well as increase of the immune-reaction of caspase-3 and desmin. The introduction of Hyphaene thebaica led to greater amelioration in the biochemical markers, apoptotic alterations, and podocyte injuries of the protected group than in the curative group.

Conclusions: Hyphaene thebaica may be advised as a good choice that can delay diabetic renal complications.

Get Citation

Keywords

diabetic nephropathy, Hyphaene thebaica, podocyte injury, apoptosis

About this article
Title

The ameliorative potential of Hyphaene thebaica on streptozotocin-induced diabetic nephropathy

Journal

Folia Morphologica

Issue

Vol 74, No 4 (2015)

Pages

447-457

Published online

2015-11-27

DOI

10.5603/FM.2015.0106

Pubmed

26620504

Bibliographic record

Folia Morphol 2015;74(4):447-457.

Keywords

diabetic nephropathy
Hyphaene thebaica
podocyte injury
apoptosis

Authors

M. AbdEl-moniem
H. N. Mustafa
H. A. Megahed
M. H. Agaibyi
G. A. Hegazy
M. A. El-Dabaa

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl